IBO on XASE, Health Care, Impact BioMedical, Inc., job postings
Measures activity, not value. Not investment advice.
Shares rose 130% in one month while a delisting notice landed and cash stands at just $21K.
WatchNet income of $1.6M over 12 months on just $38K revenue
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $21K, net loss $645K.
30 Jun 2022RevenueNet incomeNet losstallest bar $14.3M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$21K
-$645K
30 Jun 2026
$3K
-$699K
31 Mar 2026
$7K
-$2.3M
31 Dec 2025
$7K
$5.2M
30 Sep 2025
$18K
-$1.5M
30 Jun 2025
$7K
-$14.3M
31 Mar 2025
–
-$1.3M
30 Sep 2024
–
$4.2M
30 Jun 2024
–
-$884K
31 Mar 2024
–
-$998K
31 Dec 2023
–
-$1.3M
30 Sep 2023
–
-$1.2M
30 Jun 2023
–
-$1.1M
31 Mar 2023
–
-$849K
31 Dec 2022
$0
-$3.4M
30 Sep 2022
$0
-$2.2M
30 Jun 2022
$50K
-$799K
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$38K
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.6M
-$44.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$21K
$12K
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$22.9M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
$22.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.17
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
–
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
over 999
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
5.3
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$2K
bought $0, sold $2K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-18%
18 13F filers vs 22
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
3.5%
306K shares held by 13F filers (30 Sep 2026) of 8.6M outstanding (5 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
0.3%
25K shares sold short (30 Oct 2026) of 8.6M outstanding (5 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.1
25K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-6.4%
26K shares sold short in the report before, 25K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
42%
42% of off-exchange volume on 17 Nov 2026 was short sales; 1-year average 41%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
15
15 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
15 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $6.17 on 17 Nov 2026, +8.9% over 12 months (12-month range $2.68 to $9.84)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $148K in the last 12 months (the 12 months before: -$7.3M).Revenue per quarter. Revenue $21K in the latest quarter, +17% on a year earlier.Institutional holders (13F filers). 18 13F filers reported holding it in the latest 13F quarter, -14% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 17 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 30 Jun 2022: $50K; public on 6 Oct 2023
Quarter ended 30 Sep 2022: $0; public on 14 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 21 Feb 2024
Quarter ended 30 Jun 2025: $7K; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $18K; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $7K; public on 12 Mar 2026
Quarter ended 31 Mar 2026: $7K; public on 13 May 2026
Quarter ended 30 Jun 2026: $3K, -57% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $21K, +17% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
30 Sep 2024 report: 7; public on 14 Nov 2024
31 Dec 2024 report: 10; public on 14 Feb 2025
31 Mar 2025 report: 16; public on 15 May 2025
30 Jun 2025 report: 17; public on 14 Aug 2025
30 Sep 2025 report: 21; public on 14 Nov 2025
31 Dec 2025 report: 24; public on 17 Feb 2026
31 Mar 2026 report: 20; public on 15 May 2026
30 Jun 2026 report: 22; public on 14 Aug 2026
30 Sep 2026 report: 18; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is net change in 13F-reported shares at -3.5M (30 Sep 2026), 2988% below its normal reading of 122K; higher than 11% of its own history.
In 12 months: 1 major agreement, 1 completed deal, 1 delisting notice, 1 director or officer change. Results releases and routine reports are left out.
Filed
What happened
Source
18 Nov 2026
All directors, CFO and COO resigned at Effective Time; Kanans Visvanats (Chairman) and seven others appointed PubCo directors; Completed merger with PubCo's Nevada subsidiary and PubCo's acquisition of Zoar Labs, Nov 17, 2026; 8,640,000 PubCo shares issued; Completed merger; NYSE American asked to suspend trading before Nov 18, 2026 open and withdraw listing of common stockSame filing: changed shareholder rights, change of control, changed its bylaws or fiscal year
Changes and notable records, by the date each became public
18 Nov 2026Filings change
filed a director or officer change: All directors, CFO and COO resigned at Effective Time; Kanans Visvanats (Chairman) and seven others appointed PubCo directors.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
had 1.0M shares sold short in the 30 Apr 2026 report, 3.6× the same report last year.
Same report last year: 283K; its normal report is 269K.
See the evidence
This period
1.0M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
269K
Typical spread (median absolute deviation)
110K
How far from its usual level
+4.6
Same report last year
283K
History used
577 days
the 30 Apr 2026 report24 earlier reportsnormal: 269K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 15 Apr 2026 report, 9.8× the same report last year.
Same report last year: 123K; its normal report is 247K.
See the evidence
This period
1.2M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
247K
Typical spread (median absolute deviation)
94K
How far from its usual level
+6.9
Same report last year
123K
History used
562 days
the 15 Apr 2026 report24 earlier reportsnormal: 247K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 31 Mar 2026 report, 16× the same report last year.
Same report last year: 120K; its normal report is 236K.
See the evidence
This period
1.9M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
236K
Typical spread (median absolute deviation)
84K
How far from its usual level
+13.4
Same report last year
120K
History used
547 days
the 31 Mar 2026 report24 earlier reportsnormal: 236K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 13 Mar 2026 report, 146× the same report last year.
Same report last year: 9,001; its normal report is 223K.
See the evidence
This period
1.3M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
223K
Typical spread (median absolute deviation)
84K
How far from its usual level
+8.8
Same report last year
9,001
History used
529 days
the 13 Mar 2026 report24 earlier reportsnormal: 223K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 43 entries; narrow the window or the kind of data to see older ones.
Not listed: 37 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001834105
Ticker
IBO
Domain
impactbiomedinc.com
Hq location
NY|WEST HENRIETTA|14586 (1 unverified)
Name
Biolife Sugar, Inc, DSS Biolife International, Inc, DSS Biomedical International, Inc, Global BioLife, Inc and 6 more
SEC Form 13F institutional holdings81 data points30 Sep 2024 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)54 records12 Feb 2021 to 18 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)215 data points31 Dec 2021 to 5 Nov 2026
SEC Form 4 insider transactions18 records, 60 data points18 Sep 2024 to 24 Sep 2026
FINRA short interest (twice monthly)152 data points30 Sep 2024 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)1090 data points17 Sep 2024 to 17 Nov 2026